The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer immunotherapies.
mainz,Rhineland-Palatinate /germany - 16 07 2022: the biontech company building and flags in mainz germany | Image Credit: © Tobias Arhelger - stock.adobe.com
In a move to reportedly consolidate and expand its capabilities in messenger RNA (mRNA)-based medicine, BioNTech has announced plans to acquire CureVac through an all-stock transaction valued at approximately $1.25 billion (1). The acquisition aims to accelerate the development and manufacturing of next-generation mRNA immunotherapies for oncology and infectious diseases by combining the strengths of the two German-based biotechnology companies.
This acquisition forms a cornerstone of BioNTech’s long-term oncology strategy. The company intends to integrate CureVac’s proprietary mRNA platforms and advanced research infrastructure, particularly its R&D and manufacturing facilities in Tübingen, Germany, to complement existing efforts across BioNTech’s immunotherapy programs (1).
·BioNTech's acquisition of CureVac strengthens mRNA cancer immunotherapy R&D and supports its next milestone in oncology strategy execution.
·The deal enhances BioNTech’s proprietary mRNA design, delivery, and manufacturing technologies for advanced therapeutic development.
·CureVac's integration expands BioNTech’s mRNA platform, optimizing formulation and production for future oncology pipeline growth.
“This transaction is another building block in BioNTech’s oncology strategy and an investment in the future of cancer medicine,” said Ugur Sahin, MD, CEO and co-founder of BioNTech (1). “We intend to bring together complementary capabilities and leverage technologies with the goal of advancing the development of innovative and transformative cancer treatments and establishing new standards of care for various types of cancer in the coming years.”
CureVac’s scientific expertise and its progress in mRNA design and lipid nanoparticle delivery systems are expected to support BioNTech’s pan-tumor immunotherapy candidates, including its lead PD-L1xVEGF-A bispecific antibody, BNT327 (1,2).
“To me, this transaction is more than a business decision, it represents a shared commitment to leverage the full potential of mRNA as a disruptive technology to develop transformative therapies with greater scale and speed,” said Alexander Zehnder, MD, CEO of CureVac (1). “For more than two decades, both companies have operated with related ambitions, often tackling challenges from different angles. This transaction aims at combining complementary scientific capabilities, proprietary technologies, and manufacturing expertise in the mRNA field under one roof.”
BioNTech’s acquisition of CureVac reflects a broader ambition to dominate the mRNA therapeutic landscape beyond COVID-19 (1). While BioNTech is best known for co-developing the first approved mRNA vaccine with Pfizer, the company continues to invest heavily in mRNA research targeting various solid tumors and infectious diseases.
CureVac adds to this effort with an R&D pipeline that includes off-the-shelf and personalized mRNA cancer vaccines, and prophylactic vaccine candidates (1). Its technology platforms are built to enhance immunogenicity while maintaining low-dose efficiency—a key factor for scalability and safety. By combining assets, both companies aim to streamline mRNA drug development pipelines and manufacturing workflows, potentially reducing timelines for delivering clinical-stage therapies to patients. The integrated platform will be positioned to support mRNA applications from discovery to commercialization.
The deal, approved unanimously by the boards of both companies, is expected to close in 2025, pending customary regulatory clearances and a minimum 80% share acceptance rate from CureVac shareholders—although BioNTech retains the option to reduce this threshold to 75% (1).
This news comes just 10 days after BioNTech announced a global co-development and co-commercialization agreement valued at up to $11.1 billion for BNT327 (2). Under that deal, BMS will provide BioNTech with an upfront payment of $1.5 billion and an additional $2 billion in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to $7.6 billion in development, regulatory, and commercial milestones.
1. CureVac. BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer. Press Release. June 12, 2025.
2. Cole, C. BioNTech to Receive Up to $11.1 Billion in Deal with BMS to Develop Immuno-Oncology Agent. BioPharmInternational.com, June 2, 2025.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
